June 27 Financial Quick Takes: Esperion gets $125M from Oberland in funding deal for cholesterol candidates; plus Woodford, PanTheryx and Castle

Esperion, Oberland strike funding deal ahead of bempedoic acid launch
Esperion Therapeutics Inc. (NASDAQ:ESPR) forged a funding agreement with Oberland Capital tied to revenues from the sale of products

Read the full 282 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE